Royalty Pharma plc (RPRX) Stock

About Royalty Pharma plc

Royalty Pharma plc is led by CEO Pablo Legorreta, employs 75 people, headquartered in New York, US, publicly traded since 2020.

Royalty Pharma plc (RPRX) stock trades at $56.93 with a market capitalization of $25.24B. The stock is valued at a price-to-earnings (P/E) ratio of 24.15, price-to-book of 3.79, price-to-sales of 10.18. Over the past 52 weeks the stock has ranged between $35.23 and $64.38, and currently trades 11.6% below its 52-week high. It pays a dividend yielding 1.61%.

On profitability, Royalty Pharma plc generates a return on equity (ROE) of 12.25%, above the typical market average, return on capital employed of 8.24%, an operating margin of 1.00%, a net profit margin of 32.15%.

In its most recent fiscal year, Royalty Pharma plc reported annual revenue of $2.4B, net profit of $771.0M, revenue has compounded at 2.3% a year over the last five years, profit at -4.6% a year.

The balance sheet shows a debt-to-equity ratio of 1.31, a current ratio of 2.66, total assets of $19.6B, $619.0M in cash and equivalents.

RPRX has a beta of 0.43 (less volatile than the overall market).